Specialty pharmaceutical co appoints Robert Rosen to its board
A.P. Pharma Inc said it has appointed Robert Rosen to its board of directors, the news reports said.
Kevin C Tang , A.P. Pharma’s Chairman of the board said, “We are delighted that Robert has chosen to join the A.P. Pharma board. Robert’s particular expertise in commercializing oncology drugs will be instrumental, as we enter the commercialization phase with our lead product, APF530, for preventing both acute and delayed-on set chemotherapy-induced nausea and vomiting.”
Mr. Rosen is the Managing Partner of Scotia Nordic LLC. He has also served as the global head of oncology at BayerHealthCare from 2005 to 2011, where he was responsible to develop the oncology business unit for regions including the Europe, America, Japan and Asia Pacific.
During his tenure at Bayer HealthCare, he also led the launch of Nexavar to treat renal cell carcinmoma and hepatocellular carcinoma.
From period, 2002-2005, Mr. Rosen was also the Vice President of the oncology business unit at Sanofi Synthelabo, where he was responsible to develop Sanofi’s U.S.oncology business and the launch of Eloxatin for colon cancer.
A.P. Pharma also said that it has appointed Kevin C Tang as Chairman of the board and Paul Goddard, PH.D. and Gregory Turnbull has resigned from the board.
It is a specialty pharmaceutical company that develops products using its proprietary biochronomer polymer-based drug delivery platform.
- Tabuk Pharmaceuticals & Hansoh Pharma team upMedical Devices & Pharma
- Q-Centrix opens oncology solution on data management siteDigital Healthcare
- Ibex raises $38m to expand AI-based cancer diagnosticsTechnology & AI
- CVS Health launch report on the latest trends in healthcareMedical Devices & Pharma